Author:
Marques Rui Pedro,Duarte Gonçalo S.,Sterrantino Carmelo,Pais Helena Luna,Quintela António,Martins Ana Paula,Costa João
Reference40 articles.
1. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;Andre;J. Clin. Oncol.,2009
2. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial;Assenat;Oncologist,2011
3. Overal l response rate in STEAM, a randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab vs FOLFOX-bevacizumab for the first-line treatment of patients with metastatic colorectal cancer;Bendell;ASCO Gastrointestinal Cancers Symposium,2016
4. First-line chemotherapy for mCRC-a review and evidence-based algorithm;Cremolini;Nat. Rev. Clin. Oncol.,2015
5. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study;Cremolini;Lancet Oncol.,2015
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献